Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Classical hematology 1

Conditions

Adult Solid Neoplasm 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumor, Pleural 1Solid Neoplasm 1Sarcoma 1Renal Insufficiency 1Prostatic Neoplasms 1Paraproteinemias 1Osteolysis 1Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Hypercalcemia 1Hematologic Neoplasms 1Fractures, Spontaneous 1Childhood Solid Neoplasm 1Carcinoma, Renal Cell 1Breast Neoplasms 1Bone Diseases, Metabolic 1Anemia 1Amyloidosis 1

Interventions

Cyclophosphamide 10fludarabine 7trametinib 6Specimen Handling 6Mycophenolic Acid 6Whole-Body Irradiation 5Sirolimus 5Nivolumab 5Biopsy 5fludarabine phosphate 4Magnetic Resonance Spectroscopy 4dabrafenib 3Prednisone 3Melphalan 3Ipilimumab 3GSK2636771 3Filgrastim 3Electrocardiography 3Crizotinib 3CTLA-4 Antigen 3Busulfan 3palbociclib 2osimertinib 2keyhole-limpet hemocyanin 2capivasertib 2binimetinib 2adavosertib 2X-Rays 2Mesna 2Immunoglobulin G 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hematologic Neoplasms × ARQ 197 × Clear all
NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡